An ISPOR Europe 2026 session set out to answer a question every oncology dossier team now faces: how predictable are the comparators and outcomes that European HTA bodies ask for, and what does that mean for the EU joint clinical assessment (JCA)? The session compares what six agencies requested for 21 oncology and advanced therapy medicinal product (ATMP) drugs. The session page does not publish results, so this piece reads the design alongside the companion abstracts presented at the same meeting.
What the session compares
The HTA Regulation took effect in January 2025, and the first JCAs on medicinal products have started. The session description says a retrospective study compares the outcomes and comparators requested by six European HTA bodies for the 21 drugs, and compares trial data with what the HTA bodies need. The panel includes a speaker from the Haute Autorité de Santé and is moderated by Zorginstituut Nederland.
The panel will also discuss how each body decides its PICOs (Population, Intervention, Comparators, Outcomes), and whether it scopes them first or assesses what industry submits. The page does not name the six agencies and states no findings, so any headline figure should be checked against the presentation itself.
Comparators drive the divergence
Companion abstracts name comparators as the source of divergence. A review of published scoping exercises found that comparator selection was the main driver of PICO divergence. Across 35 PICO exercises in 20 indications, consolidation produced an average of 8 PICOs from 7 participating countries. An oncology simulation generated 67 PICOs across 25 countries.
The first JCA shows what this costs. The tovorafenib assessment defined 8 PICOs across 3 patient populations, but comparative evidence was included for only 1. Comparator data were unavailable for 6 PICOs and one comparison was excluded for insufficient information, so 1 of 8 scoped PICOs (12.5%) informed the final comparative assessment.
Other JCAs show the same pattern. An update on the first 18 months counted 18 JCAs by mid-June 2026, up 80% from 10 in the earlier analysis. It lists variability in comparator selection as a key theme in 11 of them. Seven of the 18 (39%) relied on single-arm studies, and indirect comparisons or external control data were proposed in 13 cases.
A comparator pyramid
A poster from UCB reviewed JCA guidance and national methods from Germany, France, Italy, Spain, Sweden, Poland and England, then tested the result with country experts. It organises comparators into tiers:
- Local standard of care. All assessed countries agreed that the standard of care most likely to be replaced in routine practice is the primary must-have comparator.
- Mandated comparators. A second tier holds centrally set "appropriate" comparators, which are prescriptive in Germany and France.
- Funding status. National formulary or public funding status matters most in Italy, Spain and Poland.
Trial-based comparators and indirect evidence were consistently treated as secondary or last-resort options that need strict justification. The experts recommended that JCA PICO scoping prioritise the lower-tier EU-core comparators and leave higher-tier options to national extensions.
Convergence is not equivalence
Agreement on comparators and endpoints does not extend to every kind of evidence. A coding of HTA guidance from 11 Member States across 9 evidence domains found comparator requirements converging on the most restrictive category in every state, and endpoint expectations converging at 100%. Convergence on indirect comparisons and biomarker-defined subgroups was only 55%, and on real-world evidence and external control arms 64%. Subgroup analyses (45%) and the extrapolation of immature evidence (45%) were the most fragmented.
What it means for market access teams
- Plan for a national tail. A JCA dossier built on one EU comparator will still meet national demands for the local standard of care, so budget for national extensions at the outset.
- Test the comparator data early. The tovorafenib case shows that scoped PICOs can outnumber the comparative evidence available. Map each likely comparator to a trial, an indirect comparison or an external control before scoping closes.
- Treat single-arm evidence as a justification task. With indirect and trial-based comparators treated as last resort, the argument for why a comparison is fit for purpose carries as much weight as the analysis.
- Read the full results. When the six-agency data are available, check which agencies were included and how many of the 21 drugs show a comparator or outcome mismatch.
To discuss how these patterns affect your evidence plan, get in touch.